论文部分内容阅读
过去的20年对多发性骨髓瘤(MM)的治疗并没有多大进展,总的存活期仅为2～4年。在伴有大量肿瘤负荷的Ⅲ期进展性MM更令人失望。作者观察综合治疗效果。临床资料Ⅲ期MM8例。8例中男4例、女4例,中位年龄41岁。K轻链型3例,IgG2例、IgA2例、非分泌型1例。治疗前有6例曾使用过各种治疗无效。本方案为先给病人进行大剂量化疗:环磷酰胺1500mg/M~2,阿霉素90mg/M~2,长春新碱1.4mg/M~2和类固醇,使病人进入短期的骨髓抑制。当病人出现血液学恢复时,即用细胞分离器以采集周围血的单个核细胞。平均每例所采集的单个核细胞数为2.6×10~3/kg,置于-196℃中保存。采集干细胞后,进行自身干细胞移植前,病人一般再进行3～4个疗程的化
The treatment of multiple myeloma (MM) has not progressed much in the past 20 years, with a total survival of only 2 to 4 years. Phase III progressive MM with high tumor burden is even more disappointing. The authors observed the effect of comprehensive treatment. Clinical data Ⅲ MM8 cases. 8 cases of 4 males and 4 females, the median age of 41 years. K light chain in 3 cases, IgG2 cases, IgA2 cases, non-secreting in 1 case. 6 cases before treatment had used a variety of treatment is invalid. The program for the first high-dose chemotherapy for patients: cyclophosphamide 1500mg / M ~ 2, doxorubicin 90mg / M ~ 2, vincristine 1.4mg / M ~ 2 and steroids, the patient into the short-term bone marrow suppression. When the patient has a hematologic recovery, use a cell separator to collect peripheral blood mononuclear cells. The average number of mononuclear cells collected per case was 2.6 × 10 ~ 3 / kg and stored at -196 ℃. After collecting the stem cells, before carrying out their own stem cell transplantation, the patients generally carry out 3 to 4 courses of chemotherapy